What is OS Therapies's proceeds from royalties received?

OS Therapies (OSTX) reported proceeds from royalties received of $150K in Q1 2024.

What does proceeds from royalties received mean?

Cash inflows generated from the licensing of intellectual property or royalty-bearing assets. This represents a recurring revenue stream derived from the commercialization of the company's proprietary technology or research.

OS Therapies OSTX Proceeds From Royalties Received

Proceeds From Royalties Received at other companies

Perrigo CompanyPRGO

$1.4M-17.6%

Elanco Animal Health Inc.ELAN

$9M—

Lightwave Logic, Inc.LWLG

$50K—

Mesabi TrustMSB

$1.63M-33.0%

Lexicon PharmaceuticalsLXRX

$12K—

Ligand PharmaceuticalsLGND

$6.98M+122%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromRoyaltiesReceived.

The official record: OS Therapies’s 10-Q, filed May 20, 2024, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's proceeds from royalties received.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's proceeds from royalties received?: OS Therapies (OSTX) reported proceeds from royalties received of $150K in Q1 2024.
What does proceeds from royalties received mean?: Cash inflows generated from the licensing of intellectual property or royalty-bearing assets. This represents a recurring revenue stream derived from the commercialization of the company's proprietary technology or research.